Radiation Therapy for Kidney Cancer

UT Southwestern offers multiple options for managing kidney cancer with radiation therapy. These treatments, which are not routinely offered elsewhere, include:

    • A combination of immunotherapy and stereotactic ablative radiotherapy (SABR) for metastatic kidney cancer (currently offered in several clinical trials with different drugs such as IL2, nivolumab, or a combination of nivolumab/ipilimumab).
      • Treatment of individual metastasis with SABR to avoid the side effects of drugs. Available for patients with a limited number of metastases in a clinical trial or even outside of a clinical trial.
        • UTSW has possibly the largest experience using SABR for the treatment of metastases. (Wang et al., Int J of Radiat Oncol, Biology, and Physics, 2017). 
        • Curative treatment with SABR for early-stage kidney cancer (currently offered in a clinical trial).
        • Treatment of tumors invading into large veins (specifically, the inferior vena cava, a main source of blood drainage into the heart) with SABR.
          • UTSW investigators were the first to report the successful use of SABR to treat tumors invading into the vena cava (Hannan et al., Cancer Biol Ther, 2015). Press Release
          • In addition, a clinical trial is ongoing to evaluate SABR treatment of tumor thrombus prior to surgery.Treatment of individual metastasis with SABR to avoid the side effects of drugs. Available for patients with a limited number of metastases in a clinical trial or even outside of a clinical trial.